已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Osimertinib versus platinum–pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis

奥西默替尼 培美曲塞 医学 内科学 肿瘤科 酪氨酸激酶抑制剂 肺癌 T790米 非小细胞肺癌 酪氨酸激酶 癌症研究 顺铂 化疗 表皮生长因子受体 癌症 埃罗替尼 吉非替尼 受体 A549电池
作者
Vassiliki A. Papadimitrakopoulou,Tony Mok,Ji‐Youn Han,Myung‐Ju Ahn,Angelo Delmonte,Suresh S. Ramalingam,Seung‐Whan Kim,Frances A. Shepherd,Janessa Laskin,Yong He,Hiroaki Akamatsu,Willemijn S.M.E. Theelen,Wu‐Chou Su,Thomas John,Martin Sebastian,Helen Mann,Michele Miranda,Gianluca Laus,Yuri Rukazenkov,Yi‐Long Wu
出处
期刊:Annals of Oncology [Elsevier BV]
卷期号:31 (11): 1536-1544 被引量:222
标识
DOI:10.1016/j.annonc.2020.08.2100
摘要

•Median OS with osimertinib was 26.8 months versus 22.5 months with platinum–pemetrexed (HR 0.87, 95% CI 0.67–1.12; P = 0.277).•The lack of a significant survival benefit could reflect high percentage (73%) of platinum–pemetrexed to osimertinib crossover.•Analysis of OS adjusted for crossover showed an HR of 0.54 (95% CI 0.18–1.60).•Among patients receiving subsequent anticancer therapy, platinum chemotherapy was the most common after osimertinib (65%).•Grade ≥3 (possibly treatment-related) adverse events were observed less frequently with osimertinib (9% versus 34% with platinum–pemetrexed). BackgroundIn AURA3 (NCT02151981), osimertinib, a third-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI), significantly prolonged progression-free survival and improved response in patients with EGFR T790M advanced non-small-cell lung cancer (NSCLC) and progression on prior EGFR-TKI treatment. We report the final AURA3 overall survival (OS) analysis.Patients and methodsAdult patients were randomized 2 : 1 to osimertinib (80 mg orally, once daily) or pemetrexed plus carboplatin/cisplatin (platinum–pemetrexed) intravenously, every 3 weeks (≤6 cycles). Patients could crossover to osimertinib on progression confirmed by blinded independent central review. OS and safety were secondary end points.ResultsA total of 279 patients were randomly assigned to receive osimertinib and 140 to platinum–pemetrexed (136 received treatment). At data cut-off (DCO; 15 March 2019), 188 patients (67%) receiving osimertinib versus 93 (66%) receiving platinum–pemetrexed had died. The hazard ratio (HR) for OS was 0.87 [95% confidence interval (CI) 0.67–1.12; P = 0.277]; the median OS was 26.8 months (95% CI 23.5–31.5) versus 22.5 months (95% CI 20.2–28.8) for osimertinib and platinum–pemetrexed, respectively. The estimated 24- and 36-month survival was 55% versus 43% and 37% versus 30%, respectively. After crossover adjustment, there was an HR of 0.54 (95% CI 0.18–1.6). Time to first subsequent therapy or death showed a clinically meaningful advantage toward osimertinib (HR 0.21, 95% CI 0.16–0.28; P < 0.001). At DCO, 99/136 (73%) patients in the platinum–pemetrexed arm had crossed over to osimertinib, 66/99 (67%) of whom had died. The most common adverse events possibly related to study treatment were diarrhea (32%; grade ≥3, 1%) and rash (grouped term; 32%; grade ≥3, <1%) in the osimertinib arm, versus nausea (47%; grade ≥3, 3%) in the platinum–pemetrexed arm.ConclusionsIn patients with T790M advanced NSCLC, no statistically significant benefit in OS was observed for osimertinib versus platinum–pemetrexed, which possibly reflects the high crossover rate of patients from platinum–pemetrexed to osimertinib.Clinical trials numberClinicalTrials.gov NCT02151981; https://clinicaltrials.gov/ct2/show/NCT02151981. In AURA3 (NCT02151981), osimertinib, a third-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI), significantly prolonged progression-free survival and improved response in patients with EGFR T790M advanced non-small-cell lung cancer (NSCLC) and progression on prior EGFR-TKI treatment. We report the final AURA3 overall survival (OS) analysis. Adult patients were randomized 2 : 1 to osimertinib (80 mg orally, once daily) or pemetrexed plus carboplatin/cisplatin (platinum–pemetrexed) intravenously, every 3 weeks (≤6 cycles). Patients could crossover to osimertinib on progression confirmed by blinded independent central review. OS and safety were secondary end points. A total of 279 patients were randomly assigned to receive osimertinib and 140 to platinum–pemetrexed (136 received treatment). At data cut-off (DCO; 15 March 2019), 188 patients (67%) receiving osimertinib versus 93 (66%) receiving platinum–pemetrexed had died. The hazard ratio (HR) for OS was 0.87 [95% confidence interval (CI) 0.67–1.12; P = 0.277]; the median OS was 26.8 months (95% CI 23.5–31.5) versus 22.5 months (95% CI 20.2–28.8) for osimertinib and platinum–pemetrexed, respectively. The estimated 24- and 36-month survival was 55% versus 43% and 37% versus 30%, respectively. After crossover adjustment, there was an HR of 0.54 (95% CI 0.18–1.6). Time to first subsequent therapy or death showed a clinically meaningful advantage toward osimertinib (HR 0.21, 95% CI 0.16–0.28; P < 0.001). At DCO, 99/136 (73%) patients in the platinum–pemetrexed arm had crossed over to osimertinib, 66/99 (67%) of whom had died. The most common adverse events possibly related to study treatment were diarrhea (32%; grade ≥3, 1%) and rash (grouped term; 32%; grade ≥3, <1%) in the osimertinib arm, versus nausea (47%; grade ≥3, 3%) in the platinum–pemetrexed arm. In patients with T790M advanced NSCLC, no statistically significant benefit in OS was observed for osimertinib versus platinum–pemetrexed, which possibly reflects the high crossover rate of patients from platinum–pemetrexed to osimertinib.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
善学以致用应助漂亮白枫采纳,获得10
3秒前
Arui发布了新的文献求助10
4秒前
4秒前
5秒前
carl发布了新的文献求助10
7秒前
xxttt发布了新的文献求助10
8秒前
漫漫完成签到 ,获得积分10
9秒前
Hello应助故意的山河采纳,获得10
9秒前
9秒前
何茂郎完成签到,获得积分10
10秒前
10秒前
听风者完成签到 ,获得积分10
11秒前
syw完成签到,获得积分10
12秒前
赘婿应助carl采纳,获得10
12秒前
13秒前
13秒前
Akim应助hq_elife采纳,获得20
14秒前
www关闭了www文献求助
14秒前
15秒前
Sophia发布了新的文献求助10
15秒前
杨行肖发布了新的文献求助10
16秒前
17秒前
allshestar完成签到 ,获得积分0
17秒前
谨慎雪碧发布了新的文献求助30
21秒前
水蜜桃完成签到 ,获得积分10
21秒前
22秒前
22秒前
22秒前
慕青应助hyhyhyhy采纳,获得10
23秒前
LienAo完成签到 ,获得积分10
23秒前
Peter完成签到,获得积分20
24秒前
土豆淀粉完成签到 ,获得积分10
24秒前
1111完成签到 ,获得积分10
24秒前
25秒前
26秒前
zsc668发布了新的文献求助10
27秒前
27秒前
杨家辉发布了新的文献求助30
27秒前
桐桐应助马尔斯采纳,获得10
28秒前
打打应助出租耳朵采纳,获得30
28秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
‘Unruly’ Children: Historical Fieldnotes and Learning Morality in a Taiwan Village (New Departures in Anthropology) 400
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3989857
求助须知:如何正确求助?哪些是违规求助? 3531994
关于积分的说明 11255679
捐赠科研通 3270758
什么是DOI,文献DOI怎么找? 1805053
邀请新用户注册赠送积分活动 882195
科研通“疑难数据库(出版商)”最低求助积分说明 809208